Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 135, Issue 10, Pages 1359-1367Publisher
SPRINGER
DOI: 10.1007/s00432-009-0577-5
Keywords
Hepatocellular carcinoma; Vascular endothelial growth factor; Platelet-derived endothelial cell growth factor; Prognosis; Tissue microarrays
Categories
Funding
- National Natural Science Foundation of China [30873039]
- Shanghai Science and Technology Development Funds [07JC14010, 06QA14012, 07SP07003]
- National Hi-Tech Research and Development Program of China [2007AA02Z479]
Ask authors/readers for more resources
To evaluate the prognosis value of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) in alpha-fetoprotein (AFP)-negative hepatocellular carcinoma (HCC) patients after curative resection. Tumor tissue microarrays (TMAs) were used to detect the expressions of VEGF and PD-ECGF in consecutive 162 AFP-negative HCC patients undergoing curative resection between 1997 and 2000 in our institute. Clinicopathologic data for these patients were evaluated. The prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. Multivariate study with Cox's proportional hazard model was used to evaluate the prognosis-related aspects. The positive rates of VEGF and PD-ECGF in tumor tissues were 59.9% (97/162) and 62.3% (101/162), respectively. Univariate analysis showed that VEGF and PD-ECGF were prognostic factors for relapse-free survival (P = 0.034 and P = 0.033, respectively). Multivariate analyses demonstrated that the co-index (VEGF/PD-ECGF) was an independent prognostic factor for overall survival and relapse-free survival (P = 0.002 and P = 0.000, respectively). The co-index of VEGF and PD-ECGF is a promising independent predictor for recurrence and survival of AFP-negative HCC patients after curative resection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available